{"name":"Impel Pharmaceuticals","slug":"impel-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":15000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":11456000,"netIncome":-106312000,"cash":88550000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2020"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Zydis","genericName":"Zydis","slug":"zydis","indication":"Other","status":"marketed"},{"name":"Zyprexa IM","genericName":"Zyprexa IM","slug":"zyprexa-im","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Zydis","genericName":"Zydis","slug":"zydis","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zyprexa IM","genericName":"Zyprexa IM","slug":"zyprexa-im","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPTDRYNlRQNXVQZWJzb3BrellLUW9LRWZWMDFYWVRvT1ZwdlNNYl9QeUpfejFqVTkzQmhfdmhFdTR6UDRqT3hWV21TbER5bUptNGZCTWpmd3dzelk5VUpUaG9oZGtFbmtlVk5hUmpUMWdzZTN6czdUc3hGbDU5ZXZiQm9WY2M?oc=5","date":"2025-05-02","type":"regulatory","source":"pharmaphorum","summary":"FDA resurrects Satsuma's nasal migraine treatment - pharmaphorum","headline":"FDA resurrects Satsuma's nasal migraine treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPT0d1MzBZMi1HYmhlcXRKTXBBeVBqWl8yWHJkc19FU2ZXZldCY0hacTM0TER0LWsyZEdlYXRxaUNhcDBsRzlPMVBFWjF1bndMWW16Ry1CM0d2eXEtakh3UXl6a0RTeFVZVUdXWGhzcFVuNGtDRTMzU0twMzBleFhYUHpneVhuMXB0Xy1FbzlNajNkTzdEa2pBTlp0eU40Z3NXQmlSSUlFT2N1WW1mSEZR0gFyQVVfeXFMTmpDbHZjTzVkVWYzUFoweFVnZkdZTzlRd0FZVGVDUW5UdVNMTTUxLU1FeHg3cmhiN0NaQVFJOU05RkJ1emxxWHVQOGk1X1N3N2hkMXJWTWxvTTJKLUM4S2FUdnEyd0lKVjVTRmludWhhLU93?oc=5","date":"2024-04-01","type":"regulatory","source":"Law360","summary":"Pharma Co. Impel's Ch. 11 Liquidation Plan Approved - Law360","headline":"Pharma Co. Impel's Ch. 11 Liquidation Plan Approved - Law360","sentiment":"positive"},{"date":"2024-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQMGpFNENISk5aU0FXQXZuMFp5UHl2OHZSeFhBNllkNTZfSTh0V0JmaWpSMnlRb3ZhYTY3V1dYN2pWYXRZb25Wc293RjNWWUREOFJlUzQ1MC1kWUxjWmwyVWRqQWZNNlBoUHFnZ2ZhZlhHQXEwQjNzT2I3TmljYlprdGFIUlVzR2xfeHRYelZoTkJENkRI?oc=5","date":"2024-02-15","type":"pipeline","source":"The Business Journals","summary":"Impel Pharmaceuticals completes sale to investors after bankruptcy filing - The Business Journals","headline":"Impel Pharmaceuticals completes sale to investors after bankruptcy filing","sentiment":"neutral"},{"date":"2024-02-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-01-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-12-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNdGItZTM2R3lJQS1tNVFlSjZNdnhFaVl5Y0VuVlJRdmYyQTJaQ1VvQnc4SU9PMzF4N0JReE8yc2tCYnhsRlRHTDF0Q05KWXRiQ2RScWQ5V2VubVp1ekl6Q0xrb0lHdzQ3YjQyYnRJVUNfam9NQThHSXRlVk5mbmp2LXZMWlhMX3Y4b1pKa01sUTRWVVFfOHVEWFhwTjFRWUNMZnRTRXdNeERReS1vUEdyM1RnT1dZRFdGa2FMWW41bkc1T3lQRldnSW5makI2WlgxNE5jQnJzam9fUy01M2pCYjVWTEZOUG9SMkVXaEZlZ0c4aXNEaFBlUGpNYlBEeWlNTnIydHVtTTRhSnRiVVMzaA?oc=5","date":"2023-12-19","type":"pipeline","source":"PR Newswire","summary":"Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of \"Stalking Horse\" Agreement to Facilitate Sale - PR Newswire","headline":"Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of \"Stalking Horse\" Agreement to Facili","sentiment":"neutral"},{"date":"2023-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQNUFqSzFsMm96QzBWYlRaMzJhVUdMdUEzUE5TVGNCalNYQ1FMWVFqQTRVYU42LV8wWkZENE9VaWxCcjN5Mjh1ZXlVZjkxeG1zSThlOHgta2xFYUkwTUtLaGg2QlpScjVmMGJXbnFZT2J3Q0E1bDc4ZmplYk9QNFZrdnVoeUMwc2lBQmtjdzNyUkZMSjhkWHpFZTJQLTEwTDI0MUNoNjl2aW82RWtZOHV5MQ?oc=5","date":"2023-10-05","type":"deal","source":"Fierce Biotech","summary":"Impel, trying to propel itself through financial woes, searches for potential buyer - Fierce Biotech","headline":"Impel, trying to propel itself through financial woes, searches for potential buyer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5BbHBLaG5ZMGUyTThSNTdCRktkT25lVUxHeWtFUDNIRFAzV1pVTUUxLVI5WDRmUGpXNURjSkZOdEtiZi1SaGd3SUNQUHQwZHEtVWQzWVc4OUxqaGZBaW5vWTZiaUc2OV90Q1I0TVRYZ25BTGM5MlB6cm5vOVd3Rjg?oc=5","date":"2023-01-20","type":"pipeline","source":"Crunchbase News","summary":"The Week’s 10 Biggest Funding Rounds: Pathalys Pharma Lands $150M; Impel Drives Away With $104M - Crunchbase News","headline":"The Week’s 10 Biggest Funding Rounds: Pathalys Pharma Lands $150M; Impel Drives Away With $104M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQb3ZDZ2FXY3RDMGpuMjlqYmQ1V0F4YV9lTGtidGxPcEZQODFCUzAtSEZGM1FXS0MtaVEyZE9XdkowUFdkN3g0WGpUTm1ZdDNNUzFDb24zY1pleWh0Z2oxLVJRZ05fMjhGbTQ5VmNjYUdvcEQxQXhBS1c4cGVOZG1uaVdGeGJ4MW9ESnp2QmtzRHJ0QmowdHFaTVZDS2wyTWFXcVRLaHF2cU9pNGhrWjdnaVZNSk8?oc=5","date":"2022-05-17","type":"pipeline","source":"Pharmaceutical Executive","summary":"Q&A With Adrian Adams, chairman and chief executive officer of Impel Pharmaceuticals - Pharmaceutical Executive","headline":"Q&A With Adrian Adams, chairman and chief executive officer of Impel Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRFZDcmwzZ2xhTWJVa0xucDdwVjk2U3EtcG1hR0pNdng4WmtGTGVjcHpaRTNfZGxlSVd1ZW80MDVOZTBUOUstZEhBSjFxM0FTcWRFRG1RSFVydG15NGltOS1JMWYxV3pqV0VxYmhnOU8zUWVsVkFHa09hUTFxeG5FVzJIMW13TS1ZcXY5NmZhLTBISFpXVTZkWG5uMXQtSzdZM0VSWFFuNHU5am5ra2ZyRTd6enNSZ2U4RDFBaFU3TS1qWHc?oc=5","date":"2022-04-25","type":"pipeline","source":"Drug Delivery Business","summary":"Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation - Drug Delivery Business","headline":"Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxPdEhoYTNaT2xIaVVPYVVKMHBxVDdSTExDeFgyN0VVaFl3a1RvMThXZHQxdkR2NkhxbDV2QXdDRHhQR0I4QnRNaHNIbmd4QVlQSmtrS25MNEVtWmNfYUo1aC1KcF8zVDVCdnRWaTRVUHZ6M0hrUnVORnRnWWpmTXBDRU5odjN0T21xa0FWblVmbTIyZUE0T3RnMUVqLWgtb1p2U1YzRmRleVB0aTViRVhJeHc0WWtuXzlXVjBod2lDTmVBaFhWdkZ0WlRZTWFZQU1VLUszYnZ3YzZDa2RkSHB5YXJYdE5VS3J0Q0J4ZFZWOEM0eVE?oc=5","date":"2022-03-17","type":"pipeline","source":"GlobeNewswire","summary":"Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree - GlobeNewswire","headline":"Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxONzlzQTdkbjFSa0dlSnRvbFBKMW9WUnBwa09Kd0Npd0d5T1NlbF9uYkVMTmFvdTVwV09zZUVrSzIyeFpqLVZiZlJhT1gyanhIaDhJel9UM3hOclBjQVU3VWswWHNuQkNUTWFLYTM2OG9ETnYtMzZqM2dpdDlHcGtlU2FRbTlRQ2R0LXJXeDdYMk9qeU55RGlsSHB1Skw4dw?oc=5","date":"2021-09-03","type":"regulatory","source":"drugdiscoverytrends.com","summary":"Impel NeuroPharma wins FDA approval for migraine nasal spray - drugdiscoverytrends.com","headline":"Impel NeuroPharma wins FDA approval for migraine nasal spray","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":15000000,"revenuePeriod":"2020-06-30","revenueHistory":[{"value":15000000,"period":"2020-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11456000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-106312000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":88550000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}